SCHEMBL22210394

SCHEMBL22210394

CC(C)(C)C1C2CN(c3ccc(F)cc3)CC21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 1/20 0.40
GFER P55789 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NOTUM Q6P988 1/20 0.39
HSD11B1 P28845 1/20 0.37
TP53 P04637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAOB P27338 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22209765 0.82 NOTUM (0.44) NOTUMCA12CA2CA9
SCHEMBL22209901 0.81 MAOB (0.37) MAOB
SCHEMBL22209630 0.81 HTR3E (0.40) MAPTLMNAALDH1A1MAPK1HTT
SCHEMBL22209763 0.81 BPTF (0.46) MAPTLMNAMAPK1NOTUMMEN1
SCHEMBL22210063 0.81 PRKCZ (0.37) NOTUMTSHR
SCHEMBL22209802 0.80 HTR3E (0.47) MAPTLMNAALDH1A1MAPK1HTT
SCHEMBL22209629 0.80 BPTF (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL22209766 0.77 ALDH1A1 (0.49) ALDH1A1MAPK1KDM4EMAOBSMN1; SMN2
SCHEMBL22209792 0.77 HRH3 (0.49) TP53KDM4EMEN1POLB
SCHEMBL22210059 0.76 TRPA1 (0.39) ALDH1A1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 MAPT 2202/4885LMNA 4575/4885ALDH1A1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.